Inipharm to Present Pharmacokinetic Data From a Phase 1 Clinical Trial of INI-822, a Small Molecule Inhibitor of HSD17B13
Inipharm, a biopharmaceutical company focused on developing therapies for fibrotic liver diseases, today announced upcoming presentations of clinical and preclinical data from INI-822, the company’s Phase 1 small molecule inhibitor of HSD17B13, currently in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), also known as NASH.
- Inipharm, a biopharmaceutical company focused on developing therapies for fibrotic liver diseases, today announced upcoming presentations of clinical and preclinical data from INI-822, the company’s Phase 1 small molecule inhibitor of HSD17B13, currently in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), also known as NASH.
- The data will be presented at the European Association for the Study of the Liver’s EASL Congress 2024, taking place June 5-8, 2024.
- In addition, exposures occurred with a half-life that will enable once daily oral dosing in future clinical studies of participants with MASH.
- These included PCs that have been shown to be elevated in liver biopsies from individuals with the inactive form of the HSD17B13 protein.